Genfit S.A.

OTCPK:GNFT.Y 株式レポート

時価総額：US$541.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genfit マネジメント

マネジメント 基準チェック /34

Genfitの CEO はM. Prigentで、 Sep2019年に任命され、 の在任期間は 6.5年です。 の年間総報酬は€ 681.95Kで、 59.5%給与と40.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.062%を直接所有しており、その価値は$ 333.78K 。経営陣と取締役会の平均在任期間はそれぞれ4年と8.8年です。

主要情報

M. Prigent

最高経営責任者

€681.9k

報酬総額

CEO給与比率59.47%
CEO在任期間6.5yrs
CEOの所有権0.06%
経営陣の平均在職期間4yrs
取締役会の平均在任期間8.8yrs

経営陣の近況

Recent updates

Seeking Alpha • Nov 21

Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions

Summary Genfit's Iqirvo received FDA approval in June 2024 for treating primary biliary cholangitis. Gilead's Livdelzi has shown superior efficacy in reducing alkaline phosphatase levels in PBC patients. Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Genfit's pipeline includes VS-01 for acute-on-chronic liver failure and GNS561 for cholangiocarcinoma. Given Iqirvo's competitive challenges and speculative pipeline, Genfit's long-term prospects remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Genfit GAAP EPS of -€0.21, revenue of €12.19M

Genfit press release (NASDAQ:GNFT): 1H GAAP EPS of -€0.21. Revenue of €12.19M (+255.4% Y/Y). Shares +3.27%.
Seeking Alpha • Sep 19

Genfit to acquire Swiss-based Versantis focused on liver diseases

Genfit (NASDAQ:GNFT) on Monday announced that it has signed an exclusivity agreement to acquire a private Swiss-based clinical stage biotechnology firm- Versantis - at an initial consideration of CHF 40M. Headquartered in Zurich, Switzerland, Versantis is focused on drug and diagnostic product development for the acute-on-chronic liver failure (ACLF) and other unmet medical needs in liver diseases. Its main asset, VS-01, is claimed as first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development for the timely recovery of ACLF and UCD. If approved, it would be the first drug to use the intraperitoneal route to simultaneously support the liver, kidney and brain, the organs that most often fail in cirrhotic patients. Consideration: This acquisition deal comprises of initial CHF 40M due at closing and consideration of up to CHF 65M upon positive Phase 2 results for VS-01 and VS-02 and regulatory approval of VS-01. Also, Versantis is eligible to receive 1/3 of the net proceeds resulting from the potential sale of the pediatric review voucher of VS-01.  Pascal Prigent, Chief Executive Officer of GENFIT, commented: “Versantis has an exciting portfolio that is complementary to GENFIT’s. We are also thrilled to welcome a talented team that has developed a strong scientific expertise in ACLF. We believe that significant synergies exist and that this acquisition will accelerate the development of several promising drug candidates in areas of high unmet needs.”
Seeking Alpha • Sep 07

Genfit S.A.: A 'Sum Of The Parts' Story

Summary Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward. An investment analysis follows in the paragraphs below. How can you govern a country which has 246 varieties of cheese?"― Charles de Gaulle We last posted a piece on small biotech outfit Genfit S.A. (GNFT) in March of 2021. We concluded saying the company has some interesting attributes, but it was probably too early to take a stake in its pending further development. The stock trades almost exactly where it did 18 months ago. No one else on Seeking Alpha has covered the company since then. Therefore, we will circle back on this name today. Seeking Alpha Company Overview: This France-based clinical stage biotech concern is focused on developing treatments primarily to treat disease of the liver and from gastroenterology. The shares currently trade just above four bucks a share and sports a market capitalization just north of $200 million. April Company Presentation Genfit is developing several compounds within its pipeline. Elafibranor, a dual agonist of PPARα and PPARδ, has shown encouraging results in mid-stage studies evaluating it to treat Primary Biliary Cholangitis or PBC. Elafibranor has Breakthrough Therapy and Orphan Drug status for PBC it should be noted. In late 2021, the company announced that it entered into an arrangement with Ipsen that will give that drug maker exclusive worldwide license to develop, manufacture and commercialize Elafibranor. April Company Presentation Genfit received a €120 million upfront payment for this license agreement and also can garner milestone payments up to €360 million (roughly 50% of this is for developmental milestones), plus tiered double-digit royalties of up to 20% on any commercialized sales. €80 million of the upfront payment was recognized as revenue in 2021, and €40 million was booked as deferred revenue and will be recognized as revenue in subsequent years following the completion of the ELATIVE double-blind study. Top-line results from that Phase 3 study evaluating Elafibranor to treat PBC should be out in the second quarter of next year. April Company Presentation The company is also working on a simple non-invasive test with Labcorp to identify at risk patients for NASH. This will be important if/when a drug is eventually approved for NASH. The company already has a significant database of patients from the work it did with its own NASH development which ended with the failure of the RESOLVE-IT trial in 2020. More data will be added with Ipsen's work on PBC. April Company Presentation The company is also working with other NASH development trials to ensure they knew steroids in their clinical trials, so that they can generate data with it. They also would naturally allow clients to use this test built on Genfit's NIS4 technology out of five blood based biomarker panels called NASHNext. That will launch from Labcorp if it is eventually approved. Genfit has an exclusive license agreement with LabCorp around this test. Genfit hopes this becomes the standard to identify at-risk NASH patients, provided a drug or drugs is approved for this widespread affliction. April Company Presentation The company also has two Phase 1 studies evaluating a candidate called NTZ, which they identified through phenotypic screening. The first Phase 1 study is focused on hepatic impairment, results from that study should be out shortly. The other Phase 1 study is focused on renal impairment. Data for this trial expected to be available in the fourth quarter of 2022. April Company Presentation Finally, late last year Genfit licensed an investigational compound from Genoscience Pharma called GNS5611. Genfit hopes to launch a Phase 1b/2 study towards the end of this year to evaluate this candidate for treating Cholangiocarcinoma (Bile Duct Cancer) which could be eligible for Orphan Drug status. Study data from this trial should be out in the first half of 2024.

CEO報酬分析

Genfit の収益と比較して、M. Prigent の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2025n/an/a

-€39m

Mar 31 2025n/an/a

-€19m

Dec 31 2024€682k€406k

€2m

Sep 30 2024n/an/a

€12m

Jun 30 2024n/an/a

€22m

Mar 31 2024n/an/a

-€3m

Dec 31 2023€664k€394k

-€29m

Sep 30 2023n/an/a

-€32m

Jun 30 2023n/an/a

-€34m

Mar 31 2023n/an/a

-€29m

Dec 31 2022€632k€375k

-€24m

Sep 30 2022n/an/a

€12m

Jun 30 2022n/an/a

€48m

Mar 31 2022n/an/a

€58m

Dec 31 2021€562k€325k

€67m

Sep 30 2021n/an/a

€14m

Jun 30 2021n/an/a

-€39m

Mar 31 2021n/an/a

-€70m

Dec 31 2020€455k€325k

-€101m

Sep 30 2020n/an/a

-€84m

Jun 30 2020n/an/a

-€67m

Mar 31 2020n/an/a

-€66m

Dec 31 2019€325k€95k

-€65m

報酬と市場: M.の 総報酬 ($USD 792.04K ) は、 US市場 ($USD 2.64M ) の同様の規模の企業の平均を下回っています。

報酬と収益: M.の報酬は増加しましたが、会社は利益を上げていません。

CEO

M. Prigent (57 yo)

6.5yrs
在職期間
€681,945
報酬

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jean-Francois Mouney
Co-Founder & Chairman of the Board8.8yrs€382.68k0.094%
$ 506.5k
M. Prigent
Chief Executive Officer6.5yrs€681.95k0.062%
$ 333.8k
Bart Staels
Co-Founder & Chairman of the Scientific Advisory Boardno dataデータなしデータなし
Thomas Baetz
Chief Financial Officer4.9yrsデータなしデータなし
Pascal Caisey
Chief Operating Officer4yrsデータなし0.0030%
$ 16.3k
Sakina Sayah-Jeanne
Chief Scientific Officerless than a yearデータなしデータなし
Jean-Christophe Marcoux
Chief Corporate Affairs Officer3yrsデータなし0.0094%
$ 50.8k
Laurent Lannoo
Corporate Secretary & Director of Legal Affairs18.2yrsデータなし0.023%
$ 122.1k
Stefanie Magner
Chief Compliance Officer & Executive VP of International Legal Affairs5yrsデータなし0.0055%
$ 30.0k
Emilie Desodt
Executive Vice President of Human Resources4yrsデータなし0.00047%
$ 2.5k
John Brozek
Executive Vice President of Data & Information Technology3yrsデータなし0.0060%
$ 32.7k
Tom Huijbers
Executive Vice President of Regulatory3yrsデータなしデータなし
4.0yrs
平均在職期間
53yo
平均年齢

経験豊富な経営陣: GNFT.Yの経営陣は 経験豊富 であると考えられます ( 4年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Jean-Francois Mouney
Co-Founder & Chairman of the Board8.8yrs€382.68k0.094%
$ 506.5k
Bart Staels
Co-Founder & Chairman of the Scientific Advisory Boardno dataデータなしデータなし
Philippe Moons
Board Observer5.1yrs€14.17k0.0021%
$ 11.3k
Florence Séjourné
Director8.8yrsデータなしデータなし
Scott L. Friedman
Member of Scientific Advisory Boardno dataデータなしデータなし
Arun Sanyal
Member of Scientific Advisory Boardno dataデータなしデータなし
Michael Trauner
Member of Scientific Advisory Boardno dataデータなしデータなし
Catherine Larue
Independent Director8.8yrs€50.14kデータなし
Vlad Ratziu
Member of Scientific Advisory Boardno dataデータなしデータなし
Anne-Helene Monsellato
Independent Director8.8yrs€45.78kデータなし
Katherine Kalin
Independent Director5.7yrs€38.39k0.010%
$ 54.3k
Eric Baclet
Independent Vice-Chairman of the Board5.7yrs€68.42k0.0024%
$ 13.0k
8.8yrs
平均在職期間
63yo
平均年齢

経験豊富なボード: GNFT.Yの 取締役会 は 経験豊富 であると考えられます ( 8.8年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/03/11 21:24
終値2026/03/09 00:00
収益2025/06/30
年間収益2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Genfit S.A. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14

アナリスト機関
Geoffrey MeachamBofA Global Research
Arnaud CadartCIC Market Solutions (ESN)
Alethia YoungDeutsche Bank